August 2012
-
Currax Pharmaceuticals has acquired US, Canadian, and Mexican rights to Onzetra Xsail intranasal dry powder sumatriptan from OptiNose, which announced that the license agreement includes a $4.8 million upfront payment, plus a 10% royalty on net… Read more . . .
-
Dance Biopharm has announced a name change, saying that the company will now be known as Aerami Therapeutics. The company, which is developing the Dance 501 insulin SMI, said that it is also moving its… Read more . . .
-
The Australian government has awarded Victoria-based Lachesis Biosciences AUS$438,000 for commercialization of the company’s rivastigmine nasal spray for the treatment of dementia in patients with Alzheimer’s Disease. The Accelerating Commercialisation grant is designed to”help businesses turn… Read more . . .
-
Device maker H&T Presspart has officially opened a new injection molding facility known as “Fenix” in Tarragona, Spain, the company said. The plant manufactures MDI actuators and other delivery device components. H&T Presspart Tarragona Managing Directors… Read more . . .
-
Senzer Pharmaceuticals said that it plans to launch its cannabinoid inhaler in the UK and elsewhere in Europe by the end of 2019 now that the device has received Class IIa Medical Device approval for the… Read more . . .
-
Russian biopharmaceutical company Generium JSC’s dornase alfa biosimilar inhalation solution has received marketing approval from Russian regulators for the treatment of cystic fibrosis, according to its partner Selexis, which developed the cell line. Genentech’s Pulmozyme dornase… Read more . . .
-
Inhalation Sciences AB (ISAB) has announced that former ExScale Bio CEO Manoush Masarrat, who has been a member of the ISAB board of directors since January 2019, will succeed Lena Heffler as ISAB CEO. In… Read more . . .
-
Canadian-based cannabis company TerrAscend has acquired exclusive distribution rights to Syqe Medical’s Syqe medical cannabis inhaler in Canada, the companies announced. The Syqe inhaler, which uses cartridges loaded with medical cannabis plant material, has been available… Read more . . .
-
Ruling on post-trial motions in a case in which a jury found in May 2019 that GSK had willfully infringed on a Vectura patent covering Ellipta, the presiding judge has upheld the jury’s award of… Read more . . .
-
Intranasal drug developer Optinose announced that it has issued $80 million in senior secured notes as part of a $150 million debt financing agreement with Pharmakon Advisors. The company plans to issue another $30 million in… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.